{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T22:28:16Z","timestamp":1775341696070,"version":"3.50.1"},"publisher-location":"Cham","reference-count":82,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031065651","type":"print"},{"value":"9783031065668","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-031-06566-8_17","type":"book-chapter","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T18:02:43Z","timestamp":1665856963000},"page":"393-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PI3K Targeting in Non-solid Cancer"],"prefix":"10.1007","author":[{"given":"Hye Na","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Ogana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cydney","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,16]]},"reference":[{"key":"17_CR1","doi-asserted-by":"crossref","unstructured":"Adam E et al (2017) The PI3Kdelta inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL. Cancers (Basel) 9(9)","DOI":"10.3390\/cancers9090121"},{"issue":"9","key":"17_CR58","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","volume":"32","author":"AY Ali","year":"2018","unstructured":"Ali AY et al (2018) Distinct roles for phosphoinositide 3-kinases gamma and delta in malignant B cell migration. Leukemia 32(9):1958\u20131969","journal-title":"Leukemia"},{"issue":"4","key":"17_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson AK et al (2015) The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 47(4):330\u2013337","journal-title":"Nat Genet"},{"issue":"1","key":"17_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20071427","volume":"410","author":"JM Backer","year":"2008","unstructured":"Backer JM (2008) The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 410(1):1\u201317","journal-title":"Biochem J"},{"issue":"20","key":"17_CR73","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM et al (2016) Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127(20):2411\u20132415","journal-title":"Blood"},{"issue":"6","key":"17_CR57","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nchembio.957","volume":"8","author":"G Bergamini","year":"2012","unstructured":"Bergamini G et al (2012) A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat Chem Biol 8(6):576\u2013582","journal-title":"Nat Chem Biol"},{"issue":"50","key":"17_CR9","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1038\/sj.onc.1209670","volume":"25","author":"C Billottet","year":"2006","unstructured":"Billottet C et al (2006) A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25(50):6648\u20136659","journal-title":"Oncogene"},{"key":"17_CR80","doi-asserted-by":"crossref","unstructured":"Blair HA (2018) Duvelisib: first global approval. Drugs","DOI":"10.1007\/s40265-018-1013-4"},{"issue":"6","key":"17_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/cyto.b.21882","volume":"98","author":"P Bonaccorso","year":"2020","unstructured":"Bonaccorso P et al (2020) Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: impact of PTEN exon 7 mutation on PI3K\/Akt and JAK-STAT signaling pathways. Cytometry B Clin Cytom 98(6):491\u2013503","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"17_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrclinonc.2014.42","volume":"11","author":"JA Burger","year":"2014","unstructured":"Burger JA, Okkenhaug K (2014) Haematological cancer: idelalisib-targeting PI3Kdelta in patients with B-cell malignancies. Nat Rev Clin Oncol 11(4):184\u2013186","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"17_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A (2018) Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer 18(3):148\u2013167","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"17_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00280-012-2043-3","volume":"71","author":"HA Burris 3rd","year":"2013","unstructured":"Burris HA 3rd (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K\/AKT\/mTOR pathway. Cancer Chemother Pharmacol 71(4):829\u2013842","journal-title":"Cancer Chemother Pharmacol"},{"issue":"31","key":"17_CR23","doi-asserted-by":"publisher","first-page":"19236","DOI":"10.1074\/jbc.272.31.19236","volume":"272","author":"D Chantry","year":"1997","unstructured":"Chantry D et al (1997) p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 272(31):19236\u201319241","journal-title":"J Biol Chem"},{"issue":"1","key":"17_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1172\/JCI99386","volume":"129","author":"S Dong","year":"2019","unstructured":"Dong S et al (2019) PI3K p110delta inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. J Clin Invest 129(1):122\u2013136","journal-title":"J Clin Invest"},{"key":"17_CR79","unstructured":"(2018) Duvelisib approved for leukemia, Lymphoma. Cancer Discov"},{"issue":"1","key":"17_CR31","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/s41467-021-23752-2","volume":"12","author":"V Ecker","year":"2021","unstructured":"Ecker V et al (2021) Targeted PI3K\/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. Nat Commun 12(1):3526","journal-title":"Nat Commun"},{"issue":"1","key":"17_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/leu.2016.202","volume":"31","author":"S Eldfors","year":"2017","unstructured":"Eldfors S et al (2017) Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia 31(1):51\u201357","journal-title":"Leukemia"},{"issue":"22","key":"17_CR35","doi-asserted-by":"publisher","first-page":"8871","DOI":"10.1073\/pnas.0903939106","volume":"106","author":"TJ Erb","year":"2009","unstructured":"Erb TJ et al (2009) Carboxylation mechanism and stereochemistry of crotonyl-CoA carboxylase\/reductase, a carboxylating enoyl-thioester reductase. Proc Natl Acad Sci U S A 106(22):8871\u20138876","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"17_CR55","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/jcp.26135","volume":"233","author":"C Evangelisti","year":"2018","unstructured":"Evangelisti C et al (2018) Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. J Cell Physiol 233(3):1796\u20131811","journal-title":"J Cell Physiol"},{"key":"17_CR77","doi-asserted-by":"crossref","unstructured":"Flinn IW et al (2018) The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL\/SLL. Blood","DOI":"10.1182\/blood-2018-05-850461"},{"issue":"8","key":"17_CR76","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"IW Flinn","year":"2018","unstructured":"Flinn IW et al (2018) Duvelisib, a novel oral dual inhibitor of PI3K-delta, gamma, is clinically active in advanced hematologic malignancies. Blood 131(8):877\u2013887","journal-title":"Blood"},{"key":"17_CR81","doi-asserted-by":"crossref","unstructured":"Flinn IW et al (2016) Dynamo: a phase 2 study demonstrating the clinical activity of duvelisib in patients with relapsed refractory indolent non-Hodgkin lymphoma. 128(22):1218\u20131218","DOI":"10.1182\/blood.V128.22.1218.1218"},{"issue":"11","key":"17_CR44","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJMe1400055","volume":"370","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Cantley LC (2014) Idelalisib\u2013a PI3Kdelta inhibitor for B-cell cancers. N Engl J Med 370(11):1061\u20131062","journal-title":"N Engl J Med"},{"issue":"3","key":"17_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1189\/jlb.71.3.495","volume":"71","author":"MT de la Fuente","year":"2002","unstructured":"de la Fuente MT et al (2002) Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71(3):495\u2013502","journal-title":"J Leukoc Biol"},{"issue":"11","key":"17_CR71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997\u20131007","journal-title":"N Engl J Med"},{"key":"17_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2017.01.035","volume":"392","author":"M Gazi","year":"2017","unstructured":"Gazi M et al (2017) The dual specificity PI3K\/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Cancer Lett 392:9\u201316","journal-title":"Cancer Lett"},{"issue":"3","key":"17_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70052-X","volume":"15","author":"JA Gilbert","year":"2014","unstructured":"Gilbert JA (2014) Idelalisib: targeting PI3Kdelta in B-cell malignancies. Lancet Oncol 15(3):e108","journal-title":"Lancet Oncol"},{"issue":"3","key":"17_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","volume":"17","author":"IB Greenwell","year":"2017","unstructured":"Greenwell IB et al (2017a) Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. Exp Rev Anticancer Ther 17(3):271\u2013279","journal-title":"Exp Rev Anticancer Ther"},{"issue":"11","key":"17_CR14","first-page":"821","volume":"31","author":"IB Greenwell","year":"2017","unstructured":"Greenwell IB, Ip A, Cohen JB (2017b) PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (williston Park) 31(11):821\u2013828","journal-title":"Oncology (williston Park)"},{"issue":"4","key":"17_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.tcb.2019.01.001","volume":"29","author":"F Gulluni","year":"2019","unstructured":"Gulluni F et al (2019) Class II PI3K functions in cell biology and disease. Trends Cell Biol 29(4):339\u2013359","journal-title":"Trends Cell Biol"},{"issue":"3","key":"17_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez A et al (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114(3):647\u2013650","journal-title":"Blood"},{"issue":"1","key":"17_CR82","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","volume":"2020","author":"A Hanlon","year":"2020","unstructured":"Hanlon A, Brander DM (2020) Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematol Am Soc Hematol Educ Prog 2020(1):346\u2013356","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"13","key":"17_CR8","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J et al (2011) The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603\u20133612","journal-title":"Blood"},{"issue":"29","key":"17_CR34","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1038\/onc.2008.40","volume":"27","author":"S Horn","year":"2008","unstructured":"Horn S et al (2008) Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 27(29):4096\u20134106","journal-title":"Oncogene"},{"issue":"1","key":"17_CR29","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41467-019-09598-9","volume":"10","author":"A Iershov","year":"2019","unstructured":"Iershov A et al (2019) The class 3 PI3K coordinates autophagy and mitochondrial lipid catabolism by controlling nuclear receptor PPARalpha. Nat Commun 10(1):1566","journal-title":"Nat Commun"},{"issue":"24","key":"17_CR43","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1128\/MCB.22.24.8580-8591.2002","volume":"22","author":"ST Jou","year":"2002","unstructured":"Jou ST et al (2002) Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22(24):8580\u20138591","journal-title":"Mol Cell Biol"},{"key":"17_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592733","volume":"10","author":"HN Kim","year":"2020","unstructured":"Kim HN et al (2020) Cadherins, selectins, and integrins in CAM-DR in leukemia. Front Oncol 10:592733","journal-title":"Front Oncol"},{"issue":"4","key":"17_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005145","volume":"4","author":"K Kok","year":"2009","unstructured":"Kok K et al (2009) Regulation of p110delta PI 3-kinase gene expression. PLoS ONE 4(4):e5145","journal-title":"PLoS ONE"},{"issue":"5","key":"17_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"MY Konopleva","year":"2011","unstructured":"Konopleva MY, Jordan CT (2011) Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 29(5):591\u2013599","journal-title":"J Clin Oncol"},{"issue":"8","key":"17_CR66","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-13-1978","volume":"20","author":"MY Konopleva","year":"2014","unstructured":"Konopleva MY et al (2014) Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 20(8):2226\u20132235","journal-title":"Clin Cancer Res"},{"key":"17_CR50","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2147\/DDDT.S142406","volume":"12","author":"G Krause","year":"2018","unstructured":"Krause G, Hassenruck F, Hallek M (2018) Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther 12:2577\u20132590","journal-title":"Drug Des Devel Ther"},{"issue":"22","key":"17_CR40","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/blood-2017-02-766204","volume":"129","author":"KA Kruth","year":"2017","unstructured":"Kruth KA et al (2017) Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood 129(22):3000\u20133008","journal-title":"Blood"},{"issue":"8","key":"17_CR51","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz G et al (2020) Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia 34(8):2184\u20132197","journal-title":"Leukemia"},{"issue":"1","key":"17_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo A et al (2018) Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19(1):87\u2013100","journal-title":"Lancet Oncol"},{"issue":"22","key":"17_CR53","doi-asserted-by":"publisher","first-page":"32641","DOI":"10.18632\/oncotarget.8702","volume":"7","author":"X Liu","year":"2016","unstructured":"Liu X et al (2016) Characterization of selective and potent PI3Kdelta inhibitor (PI3KDIN-015) for B-cell malignances. Oncotarget 7(22):32641\u201332651","journal-title":"Oncotarget"},{"issue":"12","key":"17_CR62","doi-asserted-by":"publisher","first-page":"10399","DOI":"10.18632\/oncotarget.3295","volume":"6","author":"A Lonetti","year":"2015","unstructured":"Lonetti A et al (2015) PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget 6(12):10399\u201310414","journal-title":"Oncotarget"},{"issue":"1","key":"17_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-016-0344-4","volume":"9","author":"A Lonetti","year":"2016","unstructured":"Lonetti A et al (2016) Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K\/AKT\/mTOR signaling pathway. J Hematol Oncol 9(1):114","journal-title":"J Hematol Oncol"},{"issue":"7","key":"17_CR65","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12032-015-0650-7","volume":"32","author":"JW Lu","year":"2015","unstructured":"Lu JW et al (2015) MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. Med Oncol 32(7):206","journal-title":"Med Oncol"},{"issue":"1","key":"17_CR20","first-page":"129","volume":"109","author":"CJ Luders","year":"1971","unstructured":"Luders CJ (1971) Recognition of non-ossifying bone fibroma (Jaffe-Lichtenstein) especially pathogenesis of \u201csclerotic marginal area.\u201d Z Orthop Ihre Grenzgeb 109(1):129\u2013137","journal-title":"Z Orthop Ihre Grenzgeb"},{"issue":"8","key":"17_CR75","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17474086.2018.1495557","volume":"11","author":"FR Mauro","year":"2018","unstructured":"Mauro FR et al (2018) Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Exp Rev Hematol 11(8):601\u2013611","journal-title":"Exp Rev Hematol"},{"key":"17_CR72","doi-asserted-by":"crossref","unstructured":"Migault C et al (2018) Pulmonary adverse events related to idelalisib therapy: a single centre experience. J Chemother 1\u20135","DOI":"10.1080\/1120009X.2018.1516184"},{"issue":"7","key":"17_CR69","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","volume":"21","author":"BW Miller","year":"2015","unstructured":"Miller BW et al (2015) FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res 21(7):1525\u20131529","journal-title":"Clin Cancer Res"},{"key":"17_CR36","doi-asserted-by":"crossref","unstructured":"Montano A et al (2018) New challenges in targeting signaling pathways in acute lymphoblastic leukemia by NGS approaches: an update. Cancers (Basel) 10(4)","DOI":"10.3390\/cancers10040110"},{"issue":"1","key":"17_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/pbc.24034","volume":"59","author":"N Morishita","year":"2012","unstructured":"Morishita N et al (2012) Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59(1):83\u201389","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"17_CR21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.leukres.2010.01.006","volume":"34","author":"AL Muranyi","year":"2010","unstructured":"Muranyi AL, Dedhar S, Hogge DE (2010) Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res 34(10):1358\u20131365","journal-title":"Leuk Res"},{"key":"17_CR30","doi-asserted-by":"crossref","unstructured":"Nepstad I et al (2020) The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci 21(8)","DOI":"10.3390\/ijms21082907"},{"key":"17_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.49","volume":"4","author":"LX Nguyen","year":"2014","unstructured":"Nguyen LX, Sesay A, Mitchell BS (2014) Effect of CAL-101, a PI3Kdelta inhibitor, on ribosomal RNA synthesis and cell proliferation in acute myeloid leukemia cells. Blood Cancer J 4:e228","journal-title":"Blood Cancer J"},{"issue":"5","key":"17_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/14737140.2021.1882857","volume":"21","author":"L Nikolaenko","year":"2021","unstructured":"Nikolaenko L, Liu T, Danilov AV (2021) Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. Exp Rev Anticancer Ther 21(5):481\u2013488","journal-title":"Exp Rev Anticancer Ther"},{"issue":"11","key":"17_CR78","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/ajh.25243","volume":"93","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien S et al (2018) Duvelisib, an oral dual PI3K-delta, gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol 93(11):1318\u20131326","journal-title":"Am J Hematol"},{"issue":"5","key":"17_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park S et al (2010) Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95(5):819\u2013828","journal-title":"Haematologica"},{"key":"17_CR18","doi-asserted-by":"crossref","unstructured":"Piddock RE, Bowles KM, Rushworth SA (2017) The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma. Cancers (Basel) 9(4)","DOI":"10.3390\/cancers9040029"},{"issue":"26","key":"17_CR56","doi-asserted-by":"publisher","first-page":"39784","DOI":"10.18632\/oncotarget.9289","volume":"7","author":"G Pillinger","year":"2016","unstructured":"Pillinger G et al (2016) Targeting PI3Kdelta and PI3Kgamma signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget 7(26):39784\u201339795","journal-title":"Oncotarget"},{"issue":"1","key":"17_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ajh.24568","volume":"92","author":"BK Ragon","year":"2017","unstructured":"Ragon BK et al (2017) Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol 92(1):7\u201311","journal-title":"Am J Hematol"},{"issue":"6","key":"17_CR74","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11912-018-0694-x","volume":"20","author":"J Rhodes","year":"2018","unstructured":"Rhodes J, Mato A, Sharman JP (2018) Monitoring and management of toxicities of novel B cell signaling agents. Curr Oncol Rep 20(6):49","journal-title":"Curr Oncol Rep"},{"key":"17_CR64","doi-asserted-by":"crossref","unstructured":"Richter A et al (2021) Combined application of Pan-AKT inhibitor MK-2206 and BCL-2 antagonist venetoclax in B-cell precursor acute lymphoblastic leukemia. Int J Mol Sci 22(5)","DOI":"10.3390\/ijms22052771"},{"key":"17_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.634044","volume":"9","author":"FM Roversi","year":"2021","unstructured":"Roversi FM et al (2021) Hematopoietic cell kinase (HCK) is a player of the crosstalk between hematopoietic cells and bone marrow niche through CXCL12\/CXCR4 axis. Front Cell Dev Biol 9:634044","journal-title":"Front Cell Dev Biol"},{"key":"17_CR46","doi-asserted-by":"crossref","unstructured":"Safaroghli-Azar A et al (2017) PI3K-delta inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. Anticancer Drugs 28(4):436\u2013445","DOI":"10.1097\/CAD.0000000000000477"},{"key":"17_CR2","doi-asserted-by":"crossref","unstructured":"Sanchez VE et al (2019) Targeting PI3K signaling in acute lymphoblastic leukemia. Int J Mol Sci 20(2)","DOI":"10.3390\/ijms20020412"},{"issue":"7","key":"17_CR25","first-page":"1667","volume":"63","author":"C Sawyer","year":"2003","unstructured":"Sawyer C et al (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63(7):1667\u20131675","journal-title":"Cancer Res"},{"key":"17_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fonc.2014.00099","volume":"4","author":"S Shishido","year":"2014","unstructured":"Shishido S, Bonig H, Kim YM (2014) Role of integrin alpha4 in drug resistance of leukemia. Front Oncol 4:99","journal-title":"Front Oncol"},{"issue":"11","key":"17_CR63","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2012.136","volume":"26","author":"C Simioni","year":"2012","unstructured":"Simioni C et al (2012) Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 26(11):2336\u20132342","journal-title":"Leukemia"},{"key":"17_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12935-020-01431-4","volume":"20","author":"LM Sklarz","year":"2020","unstructured":"Sklarz LM et al (2020) Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines. Cancer Cell Int 20:390","journal-title":"Cancer Cell Int"},{"issue":"40","key":"17_CR60","doi-asserted-by":"publisher","first-page":"67709","DOI":"10.18632\/oncotarget.18810","volume":"8","author":"G Stefanzl","year":"2017","unstructured":"Stefanzl G et al (2017) The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase\/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. Oncotarget 8(40):67709\u201367722","journal-title":"Oncotarget"},{"issue":"2","key":"17_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1158\/0008-5472.CAN-06-3166","volume":"67","author":"Y Tabe","year":"2007","unstructured":"Tabe Y et al (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684\u2013694","journal-title":"Cancer Res"},{"issue":"5","key":"17_CR52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","volume":"4","author":"C Tarantelli","year":"2020","unstructured":"Tarantelli C et al (2020) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Adv 4(5):819\u2013829","journal-title":"Blood Adv"},{"issue":"2","key":"17_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian SK et al (2017) Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 129(2):177\u2013187","journal-title":"Blood"},{"issue":"1","key":"17_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1):7\u201324","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"17_CR54","doi-asserted-by":"publisher","first-page":"23213","DOI":"10.18632\/oncotarget.15542","volume":"8","author":"S Ultimo","year":"2017","unstructured":"Ultimo S et al (2017) PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget 8(14):23213\u201323227","journal-title":"Oncotarget"},{"issue":"7","key":"17_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.leukres.2003.10.033","volume":"28","author":"L Wang","year":"2004","unstructured":"Wang L, Fortney JE, Gibson LF (2004) Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res 28(7):733\u2013742","journal-title":"Leuk Res"},{"issue":"10","key":"17_CR27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/aps.2015.71","volume":"36","author":"X Wang","year":"2015","unstructured":"Wang X, Ding J, Meng LH (2015) PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin 36(10):1170\u20131176","journal-title":"Acta Pharmacol Sin"},{"issue":"7716","key":"17_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41586-018-0342-5","volume":"560","author":"H Yao","year":"2018","unstructured":"Yao H et al (2018) Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 560(7716):55\u201360","journal-title":"Nature"},{"issue":"11","key":"17_CR49","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/leu.2017.80","volume":"31","author":"T Yuan","year":"2017","unstructured":"Yuan T et al (2017) Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN\/Ikaros\/miR-26b mechanism reveals a critical targetable role for PIK3CD. Leukemia 31(11):2355\u20132364","journal-title":"Leukemia"}],"container-title":["Current Topics in Microbiology and Immunology","PI3K and AKT Isoforms in Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-06566-8_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T19:40:24Z","timestamp":1665862824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-06566-8_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031065651","9783031065668"],"references-count":82,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-06566-8_17","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"16 October 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}